tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Jul 29;8(3):E424.
doi: 10.3390/vaccines8030424.
Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination
Mrityunjoy Biswas[SUP] 1 [/SUP], Tatsuya Yamazaki[SUP] 1 [/SUP], Joe Chiba[SUP] 2 [/SUP], Sachiko Akashi-Takamura[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza viruses cause annual epidemics and occasional pandemics. The high diversity of viral envelope proteins permits viruses to escape host immunity. Therefore, the development of a universal vaccine and broadly neutralizing antibodies (bnAbs) is essential for controlling various mutant viruses. Here, we review some potentially valuable bnAbs for influenza; one is a novel passive immunotherapy using a variable domain of heavy chain-only antibody (V[SUB]H[/SUB]H), and the other is polymeric immunoglobulin A (pIgA) induced by intranasal vaccination. Recently, it was reported that a tetravalent multidomain antibody (MDAb) was developed by genetic fusion of four V[SUB]H[/SUB]Hs, which are bnAbs against the influenza A or B viruses. The transfer of a gene encoding the MDAb-Fc fusion protein provided cross-protection against both influenza A and B viruses in vivo. An intranasal universal influenza vaccine, which can induce neutralizing pIgAs in the upper respiratory tract, is currently undergoing clinical studies. A recent study has revealed that tetrameric IgAs formed in nasal mucosa are more broadly protective against influenza than the monomeric and dimeric forms. These broadly neutralizing antibodies have high potential to control the currently circulating influenza virus.
Keywords: broadly neutralizing mAb (bnAb); camelid variable domain of heavy chain only antibody (VHH); cross protection; influenza virus; intranasal vaccination; multidomain antibody (MDAb); passive immunization; polymeric IgA (pIgA).
. 2020 Jul 29;8(3):E424.
doi: 10.3390/vaccines8030424.
Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination
Mrityunjoy Biswas[SUP] 1 [/SUP], Tatsuya Yamazaki[SUP] 1 [/SUP], Joe Chiba[SUP] 2 [/SUP], Sachiko Akashi-Takamura[SUP] 1 [/SUP]
Affiliations
- PMID: 32751206
- DOI: 10.3390/vaccines8030424
Abstract
Influenza viruses cause annual epidemics and occasional pandemics. The high diversity of viral envelope proteins permits viruses to escape host immunity. Therefore, the development of a universal vaccine and broadly neutralizing antibodies (bnAbs) is essential for controlling various mutant viruses. Here, we review some potentially valuable bnAbs for influenza; one is a novel passive immunotherapy using a variable domain of heavy chain-only antibody (V[SUB]H[/SUB]H), and the other is polymeric immunoglobulin A (pIgA) induced by intranasal vaccination. Recently, it was reported that a tetravalent multidomain antibody (MDAb) was developed by genetic fusion of four V[SUB]H[/SUB]Hs, which are bnAbs against the influenza A or B viruses. The transfer of a gene encoding the MDAb-Fc fusion protein provided cross-protection against both influenza A and B viruses in vivo. An intranasal universal influenza vaccine, which can induce neutralizing pIgAs in the upper respiratory tract, is currently undergoing clinical studies. A recent study has revealed that tetrameric IgAs formed in nasal mucosa are more broadly protective against influenza than the monomeric and dimeric forms. These broadly neutralizing antibodies have high potential to control the currently circulating influenza virus.
Keywords: broadly neutralizing mAb (bnAb); camelid variable domain of heavy chain only antibody (VHH); cross protection; influenza virus; intranasal vaccination; multidomain antibody (MDAb); passive immunization; polymeric IgA (pIgA).